WO2011136343A1 - Procédé de détection du cancer - Google Patents

Procédé de détection du cancer Download PDF

Info

Publication number
WO2011136343A1
WO2011136343A1 PCT/JP2011/060401 JP2011060401W WO2011136343A1 WO 2011136343 A1 WO2011136343 A1 WO 2011136343A1 JP 2011060401 W JP2011060401 W JP 2011060401W WO 2011136343 A1 WO2011136343 A1 WO 2011136343A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
tissue
diacspm
tumor
amount
Prior art date
Application number
PCT/JP2011/060401
Other languages
English (en)
Japanese (ja)
Inventor
正夫 川喜田
恭子 平松
啓二郎 鮫島
慶一 高橋
浩一 小泉
剛 桑田
Original Assignee
財団法人東京都医学総合研究所
東京都
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 財団法人東京都医学総合研究所, 東京都 filed Critical 財団法人東京都医学総合研究所
Priority to JP2012512912A priority Critical patent/JPWO2011136343A1/ja
Publication of WO2011136343A1 publication Critical patent/WO2011136343A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Definitions

  • the present invention relates to a cancer detection method capable of easily and quickly detecting the presence of a tumor at an early stage.
  • Non-Patent Document 1 Polyamine is a general term for putrescine, cadaverine, spermidine, spermine and derivatives thereof, and is a physiologically active substance widely distributed in the living body.
  • Non-Patent Document 2 Polyamines increased in the urine of cancer patients.
  • Non-patent Document 3 N 1 , N 12 -diacetylspermine (hereinafter referred to as “DiAcSpm”) exists in urine (Non-patent Document 3), and further, this substance The urinary DiAcSpm was shown to be promising as a new tumor marker by clarifying that it increases frequently in the urine of cancer patients (Non-patent Document 4). In particular, in colorectal cancer, urinary DiAcSpm was shown to increase in about 60% of patients even in early stage cancer (stage 0 and stage I) (Non-patent Document 5).
  • Non-Patent Document 6 changes in the amount of DiAcSpm produced in vivo are directly reflected in changes in urinary excretion, which is a physiological basis for making this substance a particularly good indicator of the pathogenesis of cancer. This is considered to be one (Non-Patent Document 6).
  • DiAcSpm is frequently increased in the urine of cancer patients.
  • DiAcSpm has been detected in cancer tissues isolated from living bodies. There is no one.
  • Hamaoki et al. (Non-Patent Document 7) recently studied the synthesis site of DiAcSpm, that is, the place where the acetylation reaction takes place, and that the DiAcSpm synthesis site is not a cancer tissue itself.
  • Patent Document 1 discloses expression of hepsin polypeptide in prostate tissue.
  • a method for detecting the presence or absence of the disease and evaluating the stage of prostate cancer is disclosed.
  • a mixture of equal amounts of RNA obtained from normal prostate tissues of multiple persons (4 persons) is defined as a reference pool, and the value is compared with a diseased tissue and used for diagnosis.
  • Patent Document 2 a tissue is collected from a human mammal as a biological sample, and DiAcSpm or N 1 , N 8 -diacetylspermidine (hereinafter referred to as “DiAcSpd”) is detected, and the detection result is used as an index. Diagnosing whether a non-human mammal has a tumor is disclosed.
  • the positive detection rate (about 60%) for stage 0 to stage I colorectal cancer when urinary DiAcSpm is used as an index is higher than that when CEA or CA19-9 (about 10%) is used as an index.
  • CEA or CA19-9 about 10%
  • the problem to be solved by the present invention is that a tumor detection method, a tumor condition evaluation method, and the like that can detect the presence of a tumor (particularly, the presence of early cancer) with higher accuracy, simply and quickly, and the like. Is to provide.
  • the present inventor has intensively studied to solve the above problems. As a result, when measuring the amount of DiAcSpm in the living tissue, the amount of DiAcSpm in the affected tissue (cancer tissue or suspected cancer) is measured, and the amount of DiAcSpm in the normal tissue around the affected portion is also measured. As a result, it was found that the amount of DiAcSpm per unit tissue weight was detected from the affected tissue more than the normal tissue, and the present invention was completed.
  • the present invention is as follows.
  • a method for detecting a tumor characterized by measuring the amount of N 1 , N 12 -diacetylspermine (DiAcSpm) in a living tissue and associating the obtained measurement result with a tumor (for example, the presence or absence of cancer).
  • the detection method is characterized in that the amount of DiAcSpm in the affected tissue and the amount of DiAcSpm in the normal tissue around the affected portion are both measured.
  • a method for evaluating a state of a tumor characterized by measuring the amount of N 1 , N 12 -diacetylspermine (DiAcSpm) in a biological tissue and associating the obtained measurement result with the state of the tumor, The method according to claim 1, wherein the measurement is to measure both the amount of DiAcSpm in the affected tissue and the amount of DiAcSpm in normal tissue around the affected region.
  • DiAcSpm N 1 , N 12 -diacetylspermine
  • the state of the tumor is, for example, at least one selected from the group consisting of the presence or absence of cancer, the degree of progression of cancer, the malignancy of cancer, the presence or absence of cancer metastasis, and the presence or absence of cancer recurrence.
  • the tumor for example, colon cancer, breast cancer, stomach cancer, pancreatic cancer, biliary tract cancer, lung cancer, liver cancer, urinary tract malignant tumor, uterine cancer (for example, endometrial cancer, Cervical cancer, endometrial cancer), brain tumor, myeloid leukemia and at least one selected from the group consisting of malignant lymphoma, and these tumors may be, for example, early cancer.
  • a tumor detection kit comprising an antibody against N 1 , N 12 -diacetylspermine and an acidic solution or neutral buffer for preparing a biological tissue extract.
  • the present invention it is possible to provide a tumor detection method, a tumor state evaluation method, and the like that can easily and quickly detect the presence of a tumor (particularly the presence of early cancer) with higher accuracy.
  • the DiAcSpm content per unit tissue weight is compared between living tissue derived from the same individual (same patient, etc.), that is, the affected tissue and the surrounding normal tissue.
  • the influence of the content difference due to the individual difference can be eliminated, so that the presence of the cancer tissue can be determined with extremely high accuracy.
  • the present invention provides a method showing substantially 100% in both sensitivity and specificity in one embodiment, and can detect cancer with extremely high accuracy.
  • the method of the present invention can detect, for example, early stage 0-1 early colon cancer with a substantially 100% positive detection rate, and is a test method showing a higher positive detection rate for early cancer. The task of development can be achieved.
  • the method of the present invention can minimize the time required for a series of operations to extract DiAcSpm from a biological tissue (specimen) collected from a patient and measure the DiAcSpm concentration (for example, less than 1 hour). ) Since the process does not include operations that require a particularly high level of skill, it can be easily carried out in an environment such as a general biochemical laboratory.
  • the diagnosis method is a method that is excellent in rapidity like the method of the present invention. is there.
  • the accuracy of the diagnostic method is not sufficient in terms of the detectability of the location of cancer tissue, and the method of the present invention is much more accurate than the diagnostic method.
  • the method of the present invention is much easier and quicker than the conventional histopathological examination, and the detection result can be compared as an objective numerical value.
  • the location of the cancer tissue can be determined with high accuracy. Since it has the ability to detect, it is a very useful tumor detection method that can sufficiently compensate for the shortcomings of histopathological examination that lacks rapidity.
  • the method of the present invention can be applied to biological tissues collected from mammals other than humans in addition to biological tissues collected from humans.
  • the present inventor has conducted earnest experiments and investigations from an original point of view without being bound by the conventional knowledge that acetylation of spermine is performed by macrophages in the body of a cancer-bearing individual as described above. .
  • the present inventor extracts DiAcSpm from the affected tissue (cancer tissue or tissue suspected of cancer) as a biological tissue and normal tissue around the affected region, and measures and compares the DiAcSpm concentration in these extracts.
  • DiAcSpm DiAcSpm
  • the present invention has been completed based on these findings, and is based on the measurement result of the DiAcSpm amount in the living tissue, specifically, the measurement result of the DiAcSpm amount in the affected tissue and the DiAcSpm amount in the normal tissue.
  • the present invention provides a method for detecting a tumor, a method for evaluating the state of a tumor, and the like using the measurement results of the above as indices.
  • DiAcSpm can be used as a clinical marker (tumor marker) for cancer, and an affected tissue (cancer tissue or tissue suspected of cancer) as a biological sample (living tissue) and its surroundings
  • tumor marker a clinical marker for cancer
  • affected tissue cancer tissue or tissue suspected of cancer
  • biological sample living tissue
  • examples of tumors include, but are not limited to, those shown below.
  • Respiratory lung cancer eg squamous cell carcinoma, adenocarcinoma, alveolar epithelial cancer, large cell undifferentiated cancer, small cell undifferentiated cancer, carcinoid
  • Breast Breast cancer breast Paget's disease, mammary sarcoma
  • Blood Acute myeloid leukemia acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute lymphocytic leukemia, acute undifferentiated Leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, malignant lymphoma (eg, lymphosarcoma, reticulosarcoma, Hodgkin's disease), multiple myeloma, primary macroglobulinemia
  • Gastrointestinal esophageal cancer gastric cancer, gastric / intestinal malignant lymphoma, pancreatic cancer, biliary tract cancer, gallbladder cancer, duodenal cancer, colon cancer, liver cancer
  • Female genital uterine cancer eg, endometrial cancer, cervical cancer, Endometrial cancer
  • ovarian cancer eg, uterine sarcoma (eg leiomyosarcoma, rhabdomyosarcoma, lymphosarcoma, reticulosarcoma)
  • Urinary tract malignant tumor eg prostate cancer, kidney cancer, bladder cancer, testicular tumor, urethral cancer
  • the type of cancer to be detected may be one of the above, or a combination of two or more types.
  • colon cancer urinary tract malignant tumor (eg, prostate cancer, kidney cancer, bladder cancer, testicular tumor), breast cancer, gastric cancer, pancreatic cancer, biliary tract cancer, lung cancer, liver cancer, uterine cancer (eg, endometrial cancer, Cervical cancer, endometrial cancer), brain tumor, myeloid leukemia, and malignant lymphoma.
  • the amount of DiAcSpm in the living tissue specifically, the amount of DiAcSpm in the affected tissue and the amount of DiAcSpm in the normal tissue around the affected portion are measured.
  • the amount of DiAcSpm in each tissue is measured as the amount of DiAcSpm per unit tissue weight (that is, the DiAcSpm concentration in each tissue).
  • the affected tissue may be a cancer tissue or a tissue suspected of having cancer, and is not limited.
  • the subject (test animal) from which the biological tissue is collected is preferably a human, but is not particularly limited, and mammals other than humans (non-human mammals) can also be targeted.
  • Non-human mammals include, but are not limited to, dogs, cats, cows, horses, pigs, sheep, goats, mice, rats, rabbits, guinea pigs, monkeys (including marmoset), and hamsters.
  • the “patient” can include a non-human mammal as a test animal.
  • the method for measuring the amount of DiAcSpm in a living tissue is not limited, and a desired tissue can be obtained from a cancer patient or a patient suspected of cancer (preferably the same patient) by a technique usually used in living tissue diagnosis (biopsy).
  • a method is preferred in which the collected tissue is appropriately treated with an acidic solution or neutral buffer to prepare a DiAcSpm extract or the like, and then the DiAcSpm concentration in the extract is measured.
  • the tissue collection method is not limited, and examples include surgical excision, endoscopic biopsy, needle biopsy (including echo biopsy), punch biopsy, and the like. And it can select suitably according to a site
  • the amount of DiAcSpm in the normal tissue around the affected area is also measured together with the measurement of the amount of DiAcSpm in the affected area. That is, first, both the affected tissue and the normal tissue are collected, and the DiAcSpm amount is measured for each collected tissue. Therefore, it is preferable to collect the affected tissue and normal tissue from the patient, and to measure the amount of DiAcSpm in each collected tissue at the same time, and in particular, to collect the affected tissue and normal tissue at the same time. Is more preferable.
  • the term “simultaneous period” is not limited to being completely simultaneous, and may generally be within a time range determined to be the same procedure or the same experimental system.
  • the time from tissue collection to measurement of DiAcSpm may be 1 day (within 24 hours), or within 12 hours, within 6 hours, or within 3 hours.
  • the collected affected tissue and normal tissue are temporarily stored (for example, stored at ⁇ 80 ° C.) and then used for extraction / measurement, the sampling and extraction / measurement (especially at the time of collection) are the same. If it is time, it is included in the range of the same period mentioned above. Note that any of the affected tissue and normal tissue may be collected first, extracted and measured, and is not limited.
  • the amount of the sample to be collected is not limited, and may be sufficient to obtain an extract containing DiAcSpm at a concentration that can be measured with sufficient accuracy in the measurement of the DiAcSpm concentration after the following treatment. It is preferable that it is 10 mg or more.
  • the number of samples to be collected is not limited, and a plurality of affected tissues and normal tissues can be collected and used for measuring the DiAcSpm concentration. When a plurality of tissue samples are used for measurement of the DiAcSpm concentration, the average value of each measurement result can be used as the DiAcSpm concentration of the tissue. Note that the number of samples may be one for both the affected tissue and the normal tissue.
  • the treatment method of the collected tissue is not limited, and examples thereof include chopping with a scalpel, homogenization with stirring, ultrasonic waves, and the like, as described in the examples described later.
  • the tissue thus obtained is treated (sequential treatment or the like) with an acidic solution or a neutral buffer to obtain an extract.
  • the acidic solution include 0.1M hydrochloric acid and 0.5M perchloric acid
  • examples of the neutral buffer include HEPES, Tris, and phosphoric acid (pH 6.5 to 8.0 (preferably pH 7.5)).
  • Examples thereof include, but are not limited to, a solution or a buffer solution in which DiAcSpm is effectively extracted and stably maintained.
  • the method for measuring the DiAcSpm concentration after the above treatment is not limited as long as it has sufficient detection sensitivity and measurement accuracy for DiAcSpm, and is not limited, and known analytical methods and immunological methods such as mass
  • the immunological measurement method include a metal colloid aggregation method, an immunochromatography method, an RIA method, an EIA method, an immunoturbidimetric method, and a latex aggregation method.
  • mass spectrometry particularly ESI-TOF method
  • immunochromatography particularly gold colloid aggregation
  • metal colloid aggregation particularly gold colloid aggregation
  • latex aggregation particularly gold colloid aggregation
  • Examples of the metal colloid used in the metal colloid aggregation method include colloids such as gold, silver, and selenium, and gold colloid is preferable because it is easy to use.
  • An immunoaggregation method that facilitates automation of the test without separation of the reaction solution or a washing operation is preferable, and a latex aggregation method or a gold colloid aggregation method is particularly preferable.
  • an antibody against the substance to be measured is previously bound to latex or metal colloid as a carrier. .
  • the labeled antibody previously bound to the gold colloid aggregates via DiAcSpm which is a substance to be measured.
  • the color difference (color tone change) generated at that time is optically measured, and the amount of DiAcSpm is measured.
  • DiAcSpm is measured immunologically, the method described in JP-A-2006-38594 is also preferably used.
  • an immunochromatography membrane for example, as a permeable material and membrane for allowing tissue extract to permeate (both are collectively referred to as an immunochromatography membrane), a labeled anti-DiAcSpm antibody (labeled antibody), a carrier protein and N 1 -Immunochromatography containing an acetylspermine (hereinafter referred to as “AcSpm”) acylamide bond, a protein having a large number of DiAcSpm-like structures as side chains (antigen analogue), and an antibody against the labeled antibody (capture antibody)
  • AcSpm acetylspermine
  • a membrane for example, bovine serum albumin is preferably used as the carrier protein, but is not limited thereto.
  • DiAcSpm is a low molecular weight alkylamine derivative
  • bovine serum albumin which is a carrier protein
  • AcSpm are acylamide-bonded to produce an immune antigen having many DiAcSpm-like structures as side chains.
  • An immunizing antigen can be prepared according to the method of Kawakita et al. (Hiramatsu, K. et al., J. Biochem., 124, 231-236 (1998)).
  • BSA which is a carrier protein
  • S-acetylmercaptosuccinic acid AMS
  • BSA which is a carrier protein
  • AMS S-acetylmercaptosuccinic acid
  • AcSpm is acylamide-bonded to AMS-BSA via GMBS (N- (4-Maleimidobutyryloxy) succinimide), which is a bivalent cross-linking reagent, to produce the immune antigen AcSpm-GMB-BSA.
  • GMBS N- (4-Maleimidobutyryloxy) succinimide
  • the “antibody” used in the present invention is a whole antibody molecule (which may be a polyclonal antibody or a monoclonal antibody) capable of binding to the antigen DiAcSpm, or a fragment thereof (for example, Fab or F (ab ′)). 2 fragment) or an active fragment having antigen-antibody reaction activity, specifically, Fab, Fv, recombinant Fv body, single chain Fv.
  • the antibodies (polyclonal and monoclonal antibodies and active fragments) used in the present invention can be produced by any of various methods. Methods for producing such antibodies are well known in the art.
  • the antigen prepared as described above is administered to a mammal.
  • the mammal is not particularly limited, and examples thereof include rats, mice, rabbits, and the like, and rabbits are preferable.
  • the dose of the antigen per animal is 5 to 2 mg when no adjuvant is used, and 5 to 2 mg when an adjuvant is used.
  • adjuvants include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), and aluminum hydroxide adjuvant. Immunization is performed mainly by injecting intravenously, subcutaneously or intraperitoneally.
  • the immunization interval is not particularly limited, and immunization is performed 1 to 10 times, preferably 2 to 5 times at intervals of several days to several weeks, preferably 2 to 5 weeks. And 6 to 60 days after the last immunization, antibody titer is measured by enzyme immunoassay (ELISA (enzyme-linked immunosorbent assay) or EIA (enzyme immunoassay)), radioimmunoassay (RIA), etc. Blood is collected on the day when the maximum antibody titer is shown to obtain antiserum.
  • ELISA enzyme-linked immunosorbent assay
  • EIA enzyme immunoassay
  • RIA radioimmunoassay
  • the reactivity of the polyclonal antibody in the antiserum against these proteins is measured by ELISA or the like using BSA or the like.
  • the antibody that reacts with DiAcSpm is preferably selected with higher accuracy. Specifically, the antibody exhibits strong reactivity with DiAcSpm, and (a) the cross-reactivity with N 1 -AcSpd is 0.1% or less. And / or (b) an antibody whose sum of interference to the measurement result due to cross-reaction with a DiAcSpm-like substance (DiAcSpd, Spd, Spm, etc.) is 5% or less (preferably 3% or less) preferable.
  • DiAcSpm-like substance DiAcSpd, Spd, Spm, etc.
  • the antigen prepared as described above is administered to mammals such as rats, mice, rabbits and the like.
  • the dose of the antigen per animal is 500 to 200 ⁇ g when no adjuvant is used, and 500 to 200 ⁇ g when an adjuvant is used.
  • adjuvants include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), and aluminum hydroxide adjuvant.
  • FCA Freund's complete adjuvant
  • FIA Freund's incomplete adjuvant
  • Immunization is performed mainly by injecting intravenously, subcutaneously or intraperitoneally.
  • the immunization interval is not particularly limited, and immunization is performed 1 to 10 times, preferably 2 to 5 times at intervals of several days to several weeks, preferably 2 to 5 weeks.
  • antibody-producing cells are collected 1 to 60 days, preferably 1 to 14 days after the final immunization day.
  • Examples of antibody-producing cells include spleen cells, lymph node cells, peripheral blood cells, etc., but spleen cells or local lymph node cells are preferred.
  • (ii) Cell fusion Cell fusion between antibody-producing cells and myeloma cells is performed to obtain hybridomas.
  • myeloma cells to be fused with antibody-producing cells generally available cell lines of animals such as mice can be used.
  • the cell line to be used has drug selectivity and cannot survive in a HAT selection medium (including hypoxanthine, aminopterin, and thymidine) in an unfused state, but can survive only in a state fused with antibody-producing cells. Those having the following are preferred.
  • myeloma cells include mouse myeloma cell lines such as P3X63-Ag.8.U1 (P3U1) and NS-I.
  • the myeloma cell and the antibody-producing cell are fused.
  • Cell fusion is performed by using 1 ⁇ 10 6 to 1 ⁇ 10 7 antibody-producing cells and 2 ⁇ 10 5 to 2 ⁇ 10 6 in animal cell culture media such as serum-free DMEM and RPMI-1640 media.
  • 1 / ml myeloma cells are mixed (cell ratio of antibody-producing cells to myeloma cells is preferably 5: 1), and a fusion reaction is performed in the presence of a cell fusion promoter.
  • the cell fusion promoter polyethylene glycol having an average molecular weight of 1000 to 6000 daltons can be used.
  • antibody-producing cells and myeloma cells can be fused using a commercially available cell fusion device utilizing electrical stimulation (for example, electroporation).
  • the target hybridoma is selected from the cells after cell fusion treatment.
  • the cell suspension is appropriately diluted with, for example, fetal bovine serum-containing RPMI-1640 medium, then spread on a microtiter plate, a selective medium is added to each well, and then the selective medium is appropriately replaced and cultured. I do.
  • the culture supernatant of the grown hybridoma is screened for the presence of antibodies that react with DiAcSpm.
  • Hybridoma screening is not particularly limited, and may be performed according to ordinary methods. For example, a part of the culture supernatant contained in a well grown as a hybridoma can be collected and screened by enzyme immunoassay, radioimmunoassay or the like.
  • Cloning of fused cells is performed by the limiting dilution method or the like.
  • an antibody having strong reactivity with DiAcSpm (a) an antibody having a cross-reactivity with N 1 -AcSpd of 0.1% or less, and / or Or (b) selecting a hybridoma that produces an antibody having a total interference of 5% or less (preferably 3% or less) of interference with a measurement result by cross-reaction with a DiAcSpm-like substance (DiAcSpd, Spd, Spm, etc.) Establish.
  • (iv) Collection of monoclonal antibody As a method of collecting a monoclonal antibody from an established hybridoma, a normal cell culture method or ascites formation method can be employed. In the cell culture method, the hybridoma is cultured in an animal cell culture medium such as RPMI-1640 medium containing 10% fetal bovine serum, MEM medium, or serum-free medium under normal culture conditions (eg, 37 ° C., 5% CO 2 concentration). Cultivate for 7 to 14 days and obtain antibody from the culture supernatant.
  • an animal cell culture medium such as RPMI-1640 medium containing 10% fetal bovine serum, MEM medium, or serum-free medium under normal culture conditions (eg, 37 ° C., 5% CO 2 concentration). Cultivate for 7 to 14 days and obtain antibody from the culture supernatant.
  • hybridomas In the case of the ascites formation method, about 1 ⁇ 10 7 hybridomas are administered into the abdominal cavity of a mammal derived from a myeloma cell and the same strain, and the hybridomas are proliferated in large quantities. Ascites is collected after 1-2 weeks.
  • a known method such as ammonium sulfate salting-out method, ion exchange chromatography, gel filtration, affinity chromatography or the like is appropriately selected or combined. Can be purified.
  • the detection method of the present invention is a method of detecting by associating a measurement result of the amount of DiAcSpm in a living tissue with a tumor, and specifically how to associate the measurement result with a tumor (what criteria are applied) There is no particular limitation on whether or not.
  • the ratio between the amount of DiAcSpm per unit tissue weight in the affected tissue (A) and the amount of DiAcSpm per unit tissue weight in the normal tissue around the affected tissue (B) If the lesion / normal ratio (specifically, the value of “A / B”) is 2 or more, it is determined to be positive for tumor / cancer detection, and if it is 1.0 or more and less than 2.0, it is determined to be false positive. be able to.
  • the value of the “A / B” can be determined as positive when the value is 2.6 or more, and false positive when the value is 1.0 or more and less than 2.6, If it is 2.5 or more, it is positive, if it is 1.0 or more and less than 2.5, it is determined as false positive. Also, if it is 2.4 or higher, it is positive, if it is 1.0 or higher and less than 2.4, it is determined as false positive. In addition, it is determined to be positive if it is 2.3 or more, and false positive if it is 1.0 or more and less than 2.3.
  • the above determination result can be used as a risk factor which means that there is a possibility of cancer with a certain probability.
  • the amount of DiAcSpm per unit tissue weight (nmol / g (wet tissue)) in the affected tissue is 0.9 nmol /
  • it can be judged as positive for tumor / cancer detection, and when it is 0.7 nmol / g or more and less than 0.9 nmol / g, it can be judged as false positive.
  • the amount of DiAcSpm per unit tissue weight in the affected tissue is 1.0 nmol / g or more, positive, 0.7 nmol / g or more And if it is less than 1.0 nmol / g, it can be determined as false positive, it can be determined as positive when it is 1.1 nmol / g or more, and it can be determined as false positive when it is 0.7 nmol / g or more and less than 1.1 nmol / g.
  • the level of DiAcSpm in the tissue of a cancer patient is 90% statistically different from normal tissue if the concentration in the test sample is 0.9 nmol / g or more, If the concentration in the test sample is 1.0 nmol / g or more, the statistical difference from the normal tissue is 95%, and if it is 1.3 nmol / g or more, the statistical difference from the normal tissue is 99.7% or more (almost 100%). %). Therefore, if DiAcSpm is not less than the above concentration, cancer can be detected with a predetermined probability.
  • the level of DiAcSpm may be measured using biological tissue samples derived from a plurality of patients.
  • the amount of the DiAcSpm is measured in a predetermined number of cancer patients (primary population), and the obtained measurement values are used as basic data, and the basic data and the tissue derived from each subject to be detected are detected. The amount of DiAcSpm derived can be compared.
  • the data of the measured subject patient can be incorporated into the value of the population, and the DiAcSpm level can be processed again (averaging, etc.) to increase the number of target patients (population).
  • the accuracy of the critical value of DiAcSpm can be increased, thereby increasing the detection or diagnosis accuracy.
  • the detection result can be, for example, main data or auxiliary data when performing a definitive diagnosis of cancer.
  • a comprehensive judgment should be made in combination with at least one selected from other histological examination results, serological examination results, etc. That's fine.
  • the obtained DiAcSpm amount measurement result and the tumor state can be associated with each other to evaluate or diagnose the tumor state. If it is determined as positive, it can be determined that cancer has developed or is likely to occur, and the state of the tumor can be evaluated. Therefore, in the present invention, a method for diagnosing cancer in a human or non-human mammal can also be provided based on the result of the evaluation.
  • the state of the tumor means the presence or degree of progression of the tumor, the presence or absence of onset of cancer, the progression of cancer, the malignancy of cancer, the presence or absence of cancer metastasis, the presence or absence of cancer recurrence, and the like. In the above evaluation, one of these tumor states may be selected, or a plurality may be selected in appropriate combination.
  • To evaluate the presence or absence of cancer it is determined whether or not the patient is afflicted with cancer.
  • the degree of malignancy of cancer is an index indicating how much the cancer has progressed, and benign or malignant differentiation can be made by the present invention. It is also possible to classify and evaluate the stage (Stage), and classify and evaluate so-called early cancer and advanced cancer. Cancer metastasis is evaluated by whether or not a neoplasm has appeared at a site distant from the location of the primary lesion. Recurrence is assessed by whether the cancer reappears after an intermittent period or remission.
  • DiAcSpm clearly shows a high value compared to the adjacent normal tissue regardless of the stage, regardless of whether it is a primary lesion or a metastatic lesion. it can. That is, in one embodiment of the method of the present invention, the sensitivity and specificity are substantially 100%. According to the method of the present invention, it is possible to determine whether or not a cancerous tissue is included in a specific lesion with extremely high accuracy. According to the present invention, the positive detection rate of stage 0 and I colorectal cancer (that is, early colorectal cancer) is substantially 100%, and the method of the present invention has a higher positive detection rate for early cancer. It can be said that the inspection method and the evaluation method are shown.
  • Kit The present invention provides a kit for detecting a tumor comprising an antibody against DiAcSpm and an acidic solution or neutral buffer solution (referred to as a buffer solution) for preparing a biological tissue extract.
  • the detection kit can also be used as a kit for diagnosing cancer in a human or non-human mammal.
  • the antibody, buffer solution and the like are as described above.
  • the kit of the present invention further includes sterilized water, a solution or reagent for detection reaction (gold colloid solution, BSA, sodium azide, etc.), a cleaning agent, a container used for preparing a biological tissue extract, and a detection reaction. Containers, instructions for use, etc. may be included.
  • an immunochromatography membrane for example, a labeled anti-DiAcSpm antibody (labeled antibody), a carrier protein and AcSpm are acylamide-bonded, and a DiAcSpm-like structure is located on the side.
  • An immunochromatographic membrane containing a protein having many chains (antigen analog) and an antibody against the labeled antibody (capture antibody) may also be included.
  • a container utilized for preparation of a biological tissue extract what can crush the extract
  • the one provided with both a crushing rod for crushing a tissue and a filter for collecting an extract from the crushed tissue after centrifugation in a centrifuge tube such as an Eppendorf tube is preferable.
  • the tumor detection kit including the centrifuge tube, the buffer solution, and the like, and the immunochromatography membrane is particularly useful for rapid and simple detection.
  • DiAcSpm was extracted from each patient's cancer tissue and normal tissue adjacent thereto, and colloidal gold aggregation was performed for each of the extracts
  • the DiAcSpm concentration was measured by this method.
  • the DiAcSpm concentration was also measured by ESI-TOF mass spectrometry. The details of the measurement procedure were as follows (1) to (5). In addition, about the procedure and conditions of the gold colloid aggregation method, it was as having described in the reference example mentioned later.
  • the affected tissue of a colorectal cancer patient was excised by surgery, and the cancer tissue on the excised specimen and the normal tissue adjacent to the cancerous tumor part were collected and immediately poured into liquid nitrogen and frozen. Frozen specimens were stored at -80 ° C or used immediately for DiAcSpm extraction.
  • the frozen specimen is minced on an ice bath using a dissecting scissor, 10 to 300 mg of tissue is taken, homogenized with 1 ml of 0.1 M HCl per 300 mg of tissue, and then 1 ml of 0.5 M HClO 4 solution was added and homogenized again.
  • the supernatant was recovered by centrifugation to obtain an extract.
  • DiAcSpm was quantified by ESI-TOF mass spectrometry.
  • Three samples (Sample 1 to Sample 3) were prepared by adding 0.25 nmol of 15 N-labeled DiAcSpm as an internal standard to 0.1 ml of the supernatant. 0.025 nmol of DiAcSpm standard substance was added to Sample 2 and 0.050 nmol of Sample 3 respectively.
  • 1 ml of 0.05M pyridine was added to a small column (0.2 ml) of carboxymethylcellulose previously equilibrated with 0.01M pyridine / acetic acid buffer.
  • DiAcSpm was eluted from the column with 1 ml of 0.33 M pyridine / acetic acid buffer and collected. After elution of the eluate by centrifugation under reduced pressure, a sample obtained by heptafluorobutylation according to a known method (for example, Samejima et al., Biol. Pharm. Bull., 30, 1943 (2007)) was subjected to DiAcSpm by ESI-TOF mass spectrometry. Was quantified.
  • the DiAcSpm content per unit tissue weight of the cancer tissue in all cases is at least 2.78 times the DiAcSpm content per unit tissue weight of the corresponding normal tissue.
  • Sexual tissue and normal tissue could be easily discriminated by comparing the DiAcSpm content per unit tissue weight.
  • the DiAcSpm concentration in the extract obtained from the same tissue piece was measured by ESI-TOF mass spectrometry and gold colloid aggregation method, and the measured value of DiAcSpm content per unit tissue weight was compared (FIG. 1).
  • the DiAcSpm measurement method may be any method as long as it has sufficient detection sensitivity and measurement accuracy.
  • DiAcSpm was extracted from the tumor tissue of each patient and normal tissue adjacent to each of the 5 colon polyps diagnosed as early (stage 0-I) colorectal cancer from colonoscopy findings.
  • DiAcSpm concentration was measured by colloidal gold aggregation. The details of the measurement procedure were as follows (1) to (3). In addition, about the procedure and conditions of the gold colloid aggregation method, it was as having described in the reference example mentioned later.
  • the affected tissue of a patient suspected of having colorectal cancer is removed by colonoscopy, and 4 to 15 mg of tumor tissue on the resected specimen and normal tissue adjacent to the tumor part suspected of cancer are collected. Immediately, it was frozen in liquid nitrogen. Frozen specimens were stored at -80 ° C or used immediately for DiAcSpm extraction. (2) Frozen specimens were weighed, and 6-12 ⁇ l of 0.1 M HEPES buffer (pH 7.5) per 1 mg of tissue was added and homogenized sufficiently.
  • the said buffer solution is a neutral pH, things (for example, Tris, phosphoric acid, etc.) other than HEPES can also be used. It also usually contains 2.15 mg of protease inhibitor cocktail (Sigma, P8465) per ml, but protease inhibitors are not essential for the extraction of DiAcSpm.
  • PelletPestles registered trademark
  • a homogenizer note that sample dissipation is not necessary
  • Other devices may be used as long as the method can prevent the damage and can effectively disrupt the tissue.
  • the supernatant was collected by centrifugation, and the DiAcSpm concentration was measured by a gold colloid aggregation method using a biochemical automatic analyzer.
  • the DiAcSpm content per unit tissue weight of the tumor tissue is at least 2.65 times the DiAcSpm content per unit tissue weight of the corresponding normal tissue in all cases, and cancerous tissue and normal tissue are per unit tissue weight. It was clear that it could be easily distinguished by comparing the DiAcSpm content.
  • the results of comparing DiAcSpm values between the cancerous part and the non-cancerous part for all cases of colorectal cancer examined in Examples 1 and 2 are collectively shown in FIG.
  • DiAcSpm was extracted from the tumor tissue of each patient and normal tissue adjacent to it for 9 cases of colon polyps diagnosed as moderate or highly atypical adenoma from pathological examination findings of colonoscopy specimens.
  • the DiAcSpm concentration was measured for each solution by the colloidal gold aggregation method. The details of the measurement procedure were as described in Example 2 (1) to (3). In addition, about the procedure and conditions of the gold colloid aggregation method, it was as having described in the reference example mentioned later.
  • the DiAcSpm lesion / normal ratio stays within the range of 0.3 to 1.4 times. The value was similar to that of moderate atypical adenoma.
  • DiAcSpm was extracted from the patient's cancer tissue and normal tissue adjacent thereto, and the DiAcSpm concentration was measured for each of the extracts by a gold colloid aggregation method.
  • the affected tissue of uterine cancer patients, ovarian cancer patients, and uterine fibroid patients is resected by surgery, and cancerous and benign tumor tissues on the resected specimen and normal tissues adjacent to the cancerous and benign tumor parts are removed. They were collected and immediately poured into liquid nitrogen for freezing. Frozen specimens were stored at -80 ° C or used immediately for DiAcSpm extraction.
  • DiAcSpm was extracted from the specimen, and the DiAcSpm concentration was measured for each of the extracts by a gold colloid aggregation method.
  • the details of the measurement procedure were the same as in (2) to (3) of Example 2.
  • the measurement result of the above DiAcSpm concentration was converted into the content per unit tissue weight and shown in Table 4 below.
  • the ratio of the DiAcSpm content per unit tissue weight of the tumor tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 2 or more. In all cases of uterine cancer and ovarian cancer, the ratio of the DiAcSpm content per unit tissue weight of the tumor tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 1.5 or more. On the other hand, in the uterine leiomyoma which is a benign tumor, the ratio of the DiAcSpm content per unit tissue weight of the tumor tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 0.74.
  • DiAcSpm was extracted from each patient's cancer tissue and normal tissue adjacent thereto, and the DiAcSpm concentration was measured for each of the extracts by the gold colloid aggregation method.
  • (1) Surgical excision of the affected tissue of stomach cancer patients and patients with refractory gastric ulcer, and the cancer tissue and ulcer tissue on the resected specimen, and normal tissue adjacent to the cancerous tumor part and ulcer part are collected immediately. It was frozen in liquid nitrogen. Frozen specimens were stored at -80 ° C or used immediately for DiAcSpm extraction.
  • DiAcSpm was extracted from the specimen, and the DiAcSpm concentration was measured for each of the extracts by a gold colloid aggregation method.
  • the details of the measurement procedure were the same as in (2) to (3) of Example 2.
  • the measurement result of the above DiAcSpm concentration was converted to the content per unit tissue weight and shown in Table 5 below.
  • the ratio of the DiAcSpm content per unit tissue weight of the tumor tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 2 or more. In all cases of gastric cancer, the ratio of the DiAcSpm content per unit tissue weight of the tumor tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 1.5 or more. On the other hand, in the intractable gastric ulcer, which is a benign disease, the ratio of the DiAcSpm content per unit tissue weight of the lesion tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 0.81.
  • DiAcSpm was extracted from the cancer tissue of each patient and normal tissue adjacent thereto, and the DiAcSpm concentration was measured for each of the extracts by a gold colloid aggregation method.
  • the affected tissue of a lung cancer patient was excised by surgery, and the cancerous tissue on the resected specimen and the normal tissue adjacent to the cancerous tumor part were collected and immediately placed in liquid nitrogen and frozen. Frozen specimens were stored at -80 ° C or used immediately for DiAcSpm extraction.
  • DiAcSpm was extracted from the specimen, and the DiAcSpm concentration was measured for each of the extracts by a gold colloid aggregation method.
  • the details of the measurement procedure were the same as in (2) to (3) of Example 2.
  • the measurement result of the above DiAcSpm concentration was converted to the content per unit tissue weight and shown in Table 6 below.
  • the ratio of the DiAcSpm content per unit tissue weight of the tumor tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 2 or more. In all cases of lung cancer, the ratio of the DiAcSpm content per unit tissue weight of the tumor tissue to the corresponding DiAcSpm content per unit tissue weight of the normal tissue was 1.5 or more.
  • GMBS 45 mg and N-acetylspermine trihydrochloride 147 mg, bivalent cross-linking reagent, were added in tetrahydrofuran / 50 mM phosphate buffer (pH 7.0) (1: 1 (v / v)). The mixture was mixed at room temperature for 30 minutes to produce an acetylspermine-GMB conjugate. Subsequently, 4.2 mg of hydroxylamine hydrochloride was added to 200 mg of AMS-BSA to obtain mercaptosuccinyl-BSA (MS-BSA).
  • MS-BSA mercaptosuccinyl-BSA
  • an acetylspermine-GMB-BSA was prepared by mixing acetylspermine-GMB conjugate with MS-BSA to produce an immune antigen acetylspermine-GMB-BSA in which N-acetylspermine was acylamide-linked.
  • an immunized antigen having a large number of DiAcSpm-like compounds as side chains was prepared by binding acetylspermine to an acylamide on a carrier.
  • the concentration of spermine binding BSA is absorbance at 280nm of BSA solution 1 mg / mL to A 280 is a (optical path length 1 cm) as 0.66 was calculated on the basis of the A 280 values.
  • the myeloma cells were mixed and fused with a cell fusion promoter (1000 to 6000 Da polyethylene glycol) added. After cell fusion, the desired hybridoma was selected from the cells. For this purpose, the cell suspension was diluted with fetal bovine serum-containing RPMI-1640 medium and spread on a microtiter plate. A HAT selection medium was added to each well and cultured, and cells grown in about 2 weeks were obtained as hybridomas.
  • a cell fusion promoter 1000 to 6000 Da polyethylene glycol
  • a part of the culture supernatant of the hybridoma that had proliferated was collected and screened for antibodies that react with DiAcSpm by enzyme immunoassay.
  • the fused cells were cloned by the limiting dilution method. Highly reactive to DiAcSpm, and (a) cross-reaction with N 1 -acetylspermidine is 0.1% or less, and / or (b) Hybridomas producing antibodies with a total interference of 5% or less were selected and established.
  • Monoclonal antibodies were collected from the established hybridomas by culturing for 7 to 14 days at 37 ° C. with 5% CO 2 concentration. The collected antibody was purified by ammonium sulfate salting out.
  • Second Reagent The anti-DiAcSpm antibody prepared in Section 2 above was diluted with 10 mM HEPES (pH 7.1) containing 0.05% sodium azide to a concentration of 40 ⁇ g / mL. 100 mL of this solution was added to 1 L of the gold colloid solution prepared in the above section 3, and stirred for 2 hours under refrigeration. To this mixture, add 110 mL of 10 mM HEPES (pH 7.1) containing 5.46% mannitol, 0.5% BSA, and 0.05% sodium azide, stir at 37 ° C. for 90 minutes, centrifuge at 8,000 rpm for 40 minutes, and Qing was removed.
  • 10 mM HEPES pH 7.1
  • DiAcSpm-containing biological tissue extract To 7 ⁇ L of DiAcSpm-containing biological tissue extract, 180 ⁇ L of the first reagent prepared in the above section 4 was mixed and stirred, and heated at 37 ° C. for about 5 minutes. Next, after adding and stirring 60 ⁇ L of the second reagent prepared in Section 5 above, two-point measurement of photometry points 18 to 31 was performed at a main wavelength of 540 nm and a sub-wavelength of 660 nm using Hitachi 7070 type automatic analyzer. The difference in absorbance between them was determined. The measurement time was about 10 minutes. In order to prepare a standard curve, a standard solution was prepared using a diluent. As necessary, a diluted solution was used for the preparation of a DiAcSpm-containing biological tissue extract.
  • a method for detecting a tumor a method for evaluating a tumor state, and a kit that can be used for the method, which can easily and quickly detect the presence of a tumor (particularly, the presence of early cancer) with higher accuracy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé de détection de tumeur qui peut détecter la survenue d'une tumeur avec une plus grande précision, de manière simple et rapide ; et autres. Dans le procédé de détection de tumeurs, la quantité de N1,N12-diacétylspermine dans un tissu affecté et la quantité de N1,N12-diacétylspermine dans un tissu sain qui se trouve à la périphérie du tissu affecté sont mesurées, et la survenue de la tumeur est détectée en utilisant les résultats de mesure en tant que mesures.
PCT/JP2011/060401 2010-04-28 2011-04-28 Procédé de détection du cancer WO2011136343A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012512912A JPWO2011136343A1 (ja) 2010-04-28 2011-04-28 がんの検出方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-103371 2010-04-28
JP2010103371 2010-04-28

Publications (1)

Publication Number Publication Date
WO2011136343A1 true WO2011136343A1 (fr) 2011-11-03

Family

ID=44861637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/060401 WO2011136343A1 (fr) 2010-04-28 2011-04-28 Procédé de détection du cancer

Country Status (2)

Country Link
JP (1) JPWO2011136343A1 (fr)
WO (1) WO2011136343A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019035768A (ja) * 2013-10-28 2019-03-07 株式会社サリバテック 口腔癌検出用唾液バイオマーカー
CN109870579A (zh) * 2019-02-03 2019-06-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒
US11385230B2 (en) 2010-05-21 2022-07-12 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081569A1 (fr) * 2003-03-11 2004-09-23 Trans Genic Inc. N1, n12-diacetylspermine comme marqueur de tumeurs
JP2007225605A (ja) * 2006-01-30 2007-09-06 Yamasa Shoyu Co Ltd 動物へのマクロファージの悪影響の度合いを検出する方法
JP2008050362A (ja) * 1997-07-09 2008-03-06 Nippon Kayaku Co Ltd モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
JP2009257899A (ja) * 2008-04-16 2009-11-05 Yamasa Shoyu Co Ltd マクロファージの浸潤と血管形成の度合を検出する方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008050362A (ja) * 1997-07-09 2008-03-06 Nippon Kayaku Co Ltd モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
WO2004081569A1 (fr) * 2003-03-11 2004-09-23 Trans Genic Inc. N1, n12-diacetylspermine comme marqueur de tumeurs
JP2007225605A (ja) * 2006-01-30 2007-09-06 Yamasa Shoyu Co Ltd 動物へのマクロファージの悪影響の度合いを検出する方法
JP2009257899A (ja) * 2008-04-16 2009-11-05 Yamasa Shoyu Co Ltd マクロファージの浸潤と血管形成の度合を検出する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUJIWARA, K. ET AL: "Preparation of Monoclonal Antibodies against N-(y-Maleimidobutyryloxy) succinimide (GMBS)-Conjugated Acetylspermine, and Development of an Enzyme-Linked Immunosorbent Assay (ELISA) for N1, N12- Diacetylspermine", J.BIOCHEM., vol. 124, no. 1, 1998, pages 244 - 249 *
HAMAOKI M. ET AL: "Host macrophages produce diacetylspermine related with tumorigenesis", CANCER LETT., vol. 243, no. 1, 2006, pages 128 - 134 *
KYOKO HIRAMATSU ET AL.: "Daicho Gan Oyobi Kan Ten'i Soshiki no Polyamine Gan'yuryo", JOURNAL OF JAPANESE BIOCHEMICAL SOCIETY, 10 December 2010 (2010-12-10), pages ROMBUNNO.3P-1131 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385230B2 (en) 2010-05-21 2022-07-12 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
JP2019035768A (ja) * 2013-10-28 2019-03-07 株式会社サリバテック 口腔癌検出用唾液バイオマーカー
CN109870579A (zh) * 2019-02-03 2019-06-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒
CN109870579B (zh) * 2019-02-03 2022-02-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Also Published As

Publication number Publication date
JPWO2011136343A1 (ja) 2013-07-22

Similar Documents

Publication Publication Date Title
JP5586368B2 (ja) 腫瘍マーカーとしてのｎ１，ｎ１２−ジアセチルスペルミン
CN108351358B (zh) 肝癌测试方法
JP2008539271A (ja) ｃｓＰＣＮＡイソ型抗体およびその使用
JP5616892B2 (ja) 前立腺癌バイオマーカー
US20080118935A1 (en) Methods and compositions for diagnosing neoplastic disease
WO2011136343A1 (fr) Procédé de détection du cancer
EP2499160A1 (fr) Anticorps monoclonaux contre des antigènes gmf-bêta et leurs utilisations
WO2014192974A1 (fr) Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer
KR101777259B1 (ko) En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101495225B1 (ko) Ast 양의 측정을 통한 간 질환 진단, 예후 또는 모니터링 키트 및 방법
WO2011090166A1 (fr) Marqueur de cancer de l'œsophage
JP2006199655A (ja) Ｎ１，ｎ１２−ジアセチルスペルミンに対する高親和性モノクローナル抗体
US11746146B2 (en) Antibody composition specifically recognizing an immunogenic fragment peptide of EN2 protein
JP2008122276A (ja) コラーゲン特異的分子シャペロンｈｓｐ４７の測定方法
KR102280473B1 (ko) 악성 신생물 질환의 검출을 위한 조성물 및 방법
JP5229866B2 (ja) 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
JP2007256129A (ja) 非ヒト動物の腫瘍の診断方法
JP5429723B2 (ja) 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法
US20220050110A1 (en) Use of mcm5 as a marker in semen for prostate cancer
JP2024045038A (ja) 胃癌の高度リンパ節転移を検出するためのバイオマーカー、それを用いた検出方法及び検出試薬
JP2024066398A (ja) がんの検査方法、試薬、キット及び装置
KR20110015290A (ko) 인간 Ｍｕｃ1을 인지하는 단클론 항체 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11775124

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2012512912

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11775124

Country of ref document: EP

Kind code of ref document: A1